Syndax Pharmaceuticals Inc. (SNDX) and Radius Health Inc. (NASDAQ:RDUS) Comparison side by side

Syndax Pharmaceuticals Inc. (NASDAQ:SNDX) and Radius Health Inc. (NASDAQ:RDUS) compete against each other in the Biotechnology sector. We will compare them and contrast their analyst recommendations, profitability, institutional ownership, risk, dividends, earnings and valuation.

Valuation & Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Syndax Pharmaceuticals Inc. 2.33M 64.35 74.23M -3.01 0.00
Radius Health Inc. 72.48M 12.16 251.26M -5.57 0.00

Demonstrates Syndax Pharmaceuticals Inc. and Radius Health Inc. earnings per share (EPS), gross revenue and valuation.

Profitability

Table 2 demonstrates the return on assets, return on equity and net margins of Syndax Pharmaceuticals Inc. and Radius Health Inc.

Net Margins Return on Equity Return on Assets
Syndax Pharmaceuticals Inc. -3,185.84% -91.1% -64.7%
Radius Health Inc. -346.66% -150.2% -65.2%

Liquidity

Syndax Pharmaceuticals Inc. has a Current Ratio of 5.6 and a Quick Ratio of 5.6. Competitively, Radius Health Inc.’s Current Ratio is 5.5 and has 5.4 Quick Ratio. Syndax Pharmaceuticals Inc.’s better ability to pay short and long-term obligations than Radius Health Inc.

Analyst Ratings

The table delivered features the ratings and recommendations for Syndax Pharmaceuticals Inc. and Radius Health Inc.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Syndax Pharmaceuticals Inc. 0 0 0 0.00
Radius Health Inc. 0 0 2 3.00

On the other hand, Radius Health Inc.’s potential upside is 181.65% and its consensus price target is $54.5.

Insider and Institutional Ownership

Roughly 72.4% of Syndax Pharmaceuticals Inc. shares are owned by institutional investors while 0% of Radius Health Inc. are owned by institutional investors. Competitively, 0.26% are Radius Health Inc.’s share owned by insiders.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Syndax Pharmaceuticals Inc. -5.29% -10.56% -29.9% -40.81% -40.07% -44.86%
Radius Health Inc. -4.32% -8.54% -15.11% -41.45% -41.81% -49.8%

For the past year Syndax Pharmaceuticals Inc. was less bearish than Radius Health Inc.

Summary

Syndax Pharmaceuticals Inc. beats on 7 of the 11 factors Radius Health Inc.

Syndax Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapies for various cancer indications. The companyÂ’s lead product candidate is Entinostat, which is in Phase III clinical trial for the treatment of hormone receptor positive, human epidermal growth factor receptor 2 negative, and breast cancer; and Phase 2b clinical trial. It also develops SNDX-6352, an immunoglobulin G subclass 4 isotype that binds to the ligand binding domain of CSF-1R, blocking the binding and consequent activation by natural ligands interleukin-34 and colony stimulating factor-1, and disrupting tumor-associated macrophages activity. Syndax Pharmaceuticals, Inc. has clinical collaborations with MSD International GmbH, Genentech, and Merck KGaA and Pfizer; collaborative research and development agreement with National Cancer Institute; and license agreement with Kyowa Hakko Kirin Co., Ltd. The company was founded in 2005 and is headquartered in Waltham, Massachusetts.

Radius Health, Inc., a biopharmaceutical company, develops and sells therapeutics in the areas of osteoporosis, oncology, and endocrine diseases primarily in the United States. Its product candidates include Abaloparatide-SC, an injectable subcutaneous formulation of abaloparatide, which has completed Phase III clinical trial for the treatment of patients with postmenopausal osteoporosis; and Abaloparatide-TD, a transdermal patch for use as a short wear-time transdermal patch. The company is also involved in developing RAD1901, a selective estrogen receptor down-regulator/degrader, which is in Phase I clinical trial for the treatment of metastatic breast cancer, as well as in Phase IIb clinical trial for the treatment of postmenopausal vasomotor symptoms; and RAD140, a nonsteroidal selective androgen receptor modulator for the treatment of breast cancer. It has collaborations and license agreements with 3M; Ipsen Pharma SAS; Eisai Co. Ltd.; Lonza Group Ltd.; Novartis Pharmaceuticals; and Takeda Pharmaceutical Company Limited, as well as research and development agreements with Nordic Bioscience Clinical Development VII A/S. Radius Health, Inc. was founded in 2003 and is headquartered in Waltham, Massachusetts.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.